Stéphane Bancel was appointed CEO of bioMérieux, a world leader of in vitro diagnostics for clinical and industrial applications, in January 2007. From 2000 to 2006, Stéphane worked in the United States, Great Britain and Belgium for Eli Lilly laboratories, where he successively held the positions of Managing Director, Executive Director for Global Manufacturing Strategy, Global Supply Chain and U.S. Distribution, and Supply Chain Manager. From 1995 to 1998, Stéphane worked at bioMérieux in Japan, where he was in charge of the industrial microbiology business for the Asia-Pacific region. Stéphane is a graduate of the Ecole Centrale Paris engineering school, and holds a Master of Science in biochemical engineering from the University of Minnesota, as well as a Master of Business Administration from Harvard Business School.

In 1997, Jonathan Bush co-founded athenahealth as a women’s health practice management company. Today, athenahealth is the largest and fastest growing virtual back office for medical groups in the United States, but the vision is the same: bring process integrity to the delivery of health care.

Jonathan earned a Bachelor of Arts degree with honors from WesleyanUniversityand a master’s degree with distinction in business administration from the HarvardBusinessSchool. The Boston Business Journal just recognized athenahealth as one of the top 20 ‘Best Places to Work’.

Harry Glorikian heads Scientia Advisors with 20 years of experience in the health care and life science industries. He is known worldwide as a leader in helping companies streamline their operations and accelerate their growth.

Having held senior management positions at Applied Bio Systems, Signet Laboratories, in Massachusetts, and at X-Cell Laboratories, Inc., in California, Harry has deep commercial background in diagnostics, molecular biology, proteomics, cellular biology and biodefense. His unique understanding of technologies, operations and strategy from both customer and industry player perspectives has shaped Scientia's sophisticated framework and proprietary analytic tools.

A sought-after speaker, Harry has addressed the National Institutes of Health, Molecular Medicine Tri-Conference, World Theranostics Congress and other audiences, worldwide. He has authored numerous articles for industry publications, appeared on CBS Evening News and been quoted by Dow Jones, The Boston Globe, BioWorld Today, Los Angeles Times, London Independent, Medical Device Daily, Science Magazine and many other media outlets.

Harry holds an MBA from Boston University and a BA in Biology from San Francisco State University. He serves on many advisory boards and is an avid inventor who has several patents and patents pending in the US and abroad.

Jeremy Goldberg, MBA ’89, is a skilled business development executive with over 25 years of experience, mainly focused on investing and business development in the pharmaceutical and healthcare industries. In addition to his work as Advisor at Torreya, he is an advisor to several funds focused on private equity and life sciences investments in the venture and royalty areas. He was a founding partner of ProQuest Investments in 1998, the first cancer-focused venture capital fund, where he and his partners raised over $250 million in Funds I and II to acquire positions in biotechnology, specialty pharmaceutical and medical device companies. Jeremy joined Endo Pharmaceuticals in 2003 as Managing Director, Corporate Development and was responsible for its overall corporate development activities, including structuring, negotiating and closing transactions. Jeremy’s transaction experience includes over 12 product licenses and multi-product license or acquisitions with U.S. and European companies announced while at Endo Pharmaceuticals. Prior operating experience includes roles as founding CEO or founder of three biotechnology companies that were acquired or taken public, including Versicor (Vicuron), a Sepracor spin-out later acquired by Pfizer, and operating roles at SmithKline and Becton Dickinson. He serves on the Dana Farber Cancer Institute Lank Center Visiting Committee and an NIH-Oxford affiliated board. Jeremy received his A.B. from Harvard College and M.B.A from Harvard Business School.

A physician, attorney and health care chief executive, Howard R. Grant, JD, MD, the president and chief executive officer of Lahey Clinic, has played a vital role in influencing patient safety and superior clinical care for more than two decades at some of the nation’s most preeminent health care institutions.

At Geisinger Health System, Dr. Grant was the executive vice president and chief medical officer responsible, with his administrative colleagues, for operations and budgets for 27 clinical service lines, and physician and administrator recruitment. He was also charged with aligning clinical operations with Geisinger Health Plan, a not-for-profit insurance company.

Prior to Geisinger, Dr. Grant had a long tenure at Temple University Health System, where he served in a succession of leadership roles, including chief medical officer. He was responsible for performance improvement, risk management and patient safety; integration of clinical and operational programs across multiple facilities; and clinical leadership of case and disease management.

Dr. Grant began his medical career at the Children’s Hospital of Philadelphia, and in addition to serving as a staff pediatrician, he directed quality assurance, risk management and utilization management programs. From 1992 to 1997, he served as corporate vice president for medical affairs at the Chester County Hospital.

Dr. Grant earned both his medical and law degrees from George Washington University, and holds a bachelor’s degree in political science from the University of Pennsylvania. He is a member of the American Medical Association and the American College of Physician Executives, and is a fellow of the American Academy of Pediatrics.

David graduated from Oxford University, England in 1985 with an honors degree in physics. From 1985 to 1989, he was a consumer goods brand manager in London, then moved to the USA in 1989, where he graduated with distinction from Harvard Business School in 1991.

From 1991 to 1995, David was a corporate strategy consultant with Monitor Company in Cambridge, MA and Johannesburg, South Africa, and ran all of Monitor’s worldwide training programs. In late 1995, David returned to the USA and put together the venture backed deal that created Harvard Bioscience (which began as Harvard Apparatus at Harvard Medical School in 1901), becoming President and a Director. The products are used to advance life science research at virtually all pharmaceutical and biotechnology companies and research universities worldwide. The company went public in December 2000, and Harvard Bioscience has grown from $9m in revenues in 1996 to approximately $90m in 2006 through a combination of organic growth and acquisitions, making it highly profitable.

Wycliffe Grousbeck has been Managing Partner, Governor and CEO of the Boston Celtics since December 2002, after organizing and leading a local investment group that purchased the team. Wyc is the NBA Governor of the Celtics, the Chair of the NBA Planning Committee, and is a member of the NBA Labor Relations, Finance, Compensation and Audit Committees.

Wyc named the investment group "Banner 17 LLC" to signify his primary goal, returning the Celtics to contention for their 17th World Championship. He was honored to accept the championship trophy on June 17, 2008, as the Celtics defeated the Lakers by 39 points and became World Champions for the first time in 22 years.

Prior to purchasing the Celtics with his partners, Wyc served as a General Partner of Highland Capital Partners, co-managing $1.8 billion in venture capital funds. He led successful investments in medical technology, software and health care services. His earlier career included four years as a venture capital lawyer in Silicon Valley and two years as a manager in a public biotech company.

Wyc holds a bachelor's degree in history from Princeton University (1983), a law degree from the University of Michigan (1986) and an MBA from Stanford Business School where he was a Miller Scholar (1992). At Princeton he rowed on the undefeated varsity eight that claimed the Ivy League and national rowing championships in 1983.

Robert Huckman is a Professor of Business Administration at Harvard Business School, as well as the faculty co-chair of the HBS Healthcare Initiative, a faculty research fellow in the health care program of the National Bureau of Economic Research, and the co-chair of the management track of Harvard's doctoral program in health policy.

Professor Huckman's research focuses on the linkages between organizational characteristics and operating performance, with an emphasis on the health care industry. His articles have appeared in publications including the American Economic Journal, the American Economic Review, Harvard Business Review, Health Affairs, the Journal of Health Economics,Management Science, the New England Journal of Medicine, Organization Science, and the Strategic Management Journal. His worked has been cited in numerous media outlets, including a 2007 profile in The Financial Times. He is an associate editor of Management Science, a senior editor of Production and Operations Management, and a member of the editorial review board of Organization Science.

Professor Huckman received a Ph.D. in Business Economics from Harvard University and an A.B. in Public Policy, summa cum laude, from Princeton University, where he was elected to Phi Beta Kappa.

Prior to his graduate studies, Professor Huckman was a Principal and Founding Equity Member of Stamos Associates, Inc., a strategy and operations consulting firm serving clients in the health care industry. In 1997, Stamos Associates was acquired by Perot Systems, Inc. Professor Huckman has also worked at Booz Allen & Hamilton, Inc.

Jeff Kindler is the former Chairman and Chief Executive Officer of Pfizer, the world's largest research-based biopharmaceutical company, from which he retired in December 2010. He joined Pfizer in January 2002 as Executive Vice President and General Counsel. Prior to his appointment as CEO in July 2006, he was promoted to the position of a Vice Chairman of the company and a member of its four-person Executive Committee with responsibility for Pfizer's worldwide legal, compliance, communications, government relations, corporate citizenship, policy development, and global security groups.

Jeff began his legal career as an attorney at the Federal Communications Commission, then served as law clerks in both the U.S. Court of Appeals of the D.C. Circuit and the U.S. Supreme Court. He joined the law firm of Williams & Connolly, eventually becoming a Partner, and later joined General Electric as Vice President of Litigation and Legal Policy. After that, Jeff joined McDonald's Corporation as Executive Vice President and General Counsel.

He previously served on the Federal Reserve Bank of New York, the President’s Export Council, the Business Roundtable, the Shanghai Mayor’s Business Advisory Council, Catalyst, the United Way of New York City, the Legal Aid Society, Lincoln Center, and as Chairman of the U.S.-Japan Business Council. He currently serves on the boards of Tufts University, Ronald McDonald House Charities and the Manhattan Theatre Club, and is a member of the President’s Management Advisory Board.

Paul LaViolette joined SVLS in January 2009.  He brings over 28 years of global medical technology marketing and general management experience. Paul was most recently Chief Operating Officer at Boston Scientific Corporation (BSC), an $8 billion medical device leader. During his 15 years at BSC, he served as COO, Group President, President-Cardiology and President-International as the company grew revenues over 20 times. Paul integrated two dozen acquisitions and led extensive product development, operations and worldwide commercial organizations. Paul previously held marketing and general management positions at CR Bard, and various marketing roles at Kendall (Tyco). He served on the boards of Urologix, Percutaneous Valve Technologies and Advamed and currently serves on the boards of Cameron Health, CardioFocus, Conceptus, DC Devices, Direct Flow Medical, DJO Global, Thoratec, TransEnterix, Trans 1 ValenTx and Medical Device Manufacturers Association (MDMA).

Paul received his BA in Psychology from Fairfield University and his MBA from Boston College.

Martin Madaus is an independent consultant for the life science industry. From January 2005 to July 2010, he served as President, Chairman and CEO of Millipore Corporation, where he transformed the company from a filtration business to a leading life science corporation. Under Dr. Madaus’ leadership, Millipore completed several strategic acquisitions, expanded core capabilities, doubled annual revenues, expanded global operations and improved shareholder value by 114%. Dr. Madaus was instrumental in facilitating Millipore’s acquisition by Merck KGaA in July 2010.

Before joining Millipore, Dr. Madaus served as President, CEO and head of North American operations for Roche Diagnostics Corporation. Prior to that, he served as Vice President of Business Development for Roche Molecular Diagnostics, and General Manager of Boehringer Mannheim Canada. From 1989 to 1998, he held a number of senior-level sales, marketing and product management positions with Boehringer Mannheim Corporation in both Germany and the United States.

Before beginning his corporate career, Dr. Madaus was a practicing equine veterinarian in Germany and Spain. He holds a D.M.V. and a Ph.D. in veterinary medicine, and is a Director of Mettler Toledo International and Quanterix Corporation.

Robert Musslewhite serves as Chief Executive Officer of The Advisory Board Company (Nasdaq: ABCO). Mr. Musslewhite joined the firm in 2003, initially serving in executive roles in strategic planning and new product development. In 2007, he was named Executive Vice President and general manager in charge of software-based programs, and he became CEO the following year. Prior to joining The Advisory Board Company, Mr. Musslewhite was an Associate Principal in the Washington, DC, Amsterdam, and Dallas offices of McKinsey & Company, where he served a range of clients across the consumer products and other industries and was a co-leader of McKinsey’s Pricing Center. Mr. Musslewhite holds a JD from Harvard Law School and an AB in Economics from Princeton University.

Dr. Samuel Nussbaum is Executive Vice President, Clinical Health Policy, Chief Medical Officer for WellPoint, Inc., and Interim President of WellPoint’s Comprehensive Health Solutions Business Unit.

Within Clinical Health Policy, Nussbaum oversees corporate medical policy, clinical pharmacy programs, and public health policy.  He also has responsibility for HealthCore, WellPoint’s clinical outcomes research subsidiary.  As the leader of Comprehensive Health Solutions, which includes WellPoint’s provider relations, care and disease management, imaging management, personal health guidance companies, and WellPoint’s pharmacy solutions group, Nussbaum is responsible for focusing on the issues of medical cost, quality of care and enhancing member value through innovative health solutions.

Dr. Nussbaum has served as president of the Disease Management Association of America, Chairman of the National Committee for Quality Health Care, as Chair of America's Health Insurance Plan's (AHIP) Chief Medical Officer Leadership Council and as a member of the AHIP Board, and currently serves on the National Quality Forum (NQF) Board and on the Secretary of Health and Human Services Advisory Committee on Genetics, Health, and Society.  He received the 2004 Physician Executive Award of Excellence from the AmericanCollegeof Physician Executives and Modern Physician magazine.  Dr. Nussbaum is professor of clinical medicine at Washington University School of Medicine and serves as adjunct professor at the Olin School of Business, Washington University.  He has also served as executive vice president, Medical Affairs and System Integration, of the BJC Health Care, where he led integrated clinical services across the health system and served as President of its medical group.

Dr. Nussbaum earned his medical degree from Mount Sinai School of Medicine, trained in internal medicine at StanfordUniversityMedicalCenterand Massachusetts GeneralHospitaland in endocrinology and metabolism at Harvard and Massachusetts GeneralHospital, where he directed the Endocrine Clinical Group.  Dr. Nussbaum served as a professor at HarvardMedicalSchool, where his clinical and basic research has led to new therapies to treat skeletal disorders and new technologies to measure hormones in blood.

Tom Robinson is an active member of Russell Reynolds Associates’ Global Medical Technology Practice, and previously led the Global Medical Technology Practice at another leading executive search firm for 10 years. He is also active within the CEO/Board Services and Biotechnology practices. Building upon 20 years of industry experience in top healthcare companies, he leads senior level searches in these three areas for clients ranging from start-ups to Fortune 100 companies. Previously, Tom was President of the emerging markets business at Boston Scientific Corporation, responsible for all markets in Europe, Asia, Latin America and Canada, as well as President of Brunswick Biomedical, a cardiology startup, and General Manager of a business unit of Cardinal Health. Tom started his healthcare career at American Hospital Supply Corporation. Additionally, Tom’s Board of Director experience includes Chairman of the Compensation Committee for Cynosure; Sanuwave; Harvard Business School Healthcare Alumni Association; and a Co-Chair of the Global Annual Conference. Tom received his MBA from Harvard Business School and his BA in mathematics and economics from Brown University.

Justin Silver is a Vice President with Radius. Prior to joining Radius in 2008 as a Senior Associate, Justin served as an Associate with Ferghana Partners, where he specialized in life science and medical device private placements and corporate partnering transactions. Justin has also worked for the healthcare team at New Enterprise Associates, where he concentrated on venture capital financings and strategic advisory work for its portfolio companies.

He currently serves as a board observer of Ambit, Inc., Healthsense, Inc., Management Health Solutions, Inc., and Resolvyx, Inc, and also works closely with Biostorage Technologies, Inc., Endogastric Solutions, Inc., and Aethon, Inc. Justin is also a mentor with BluePrint Health, a startup accelerator that helps entrepreneurs improve the health and wellness industry.

Justin received a BS in Business Administration from Washington University in St. Louis and a MS in Biochemistry and Molecular Biology from Georgetown University, where he graduated first in his class. Justin is a graduate of the Harvard Business School, where he received the Dean's Award for leadership within the Harvard community and where he served as Co-President of the Harvard Business School Healthcare Club.

Mr. Smith joined Intuitive Surgical as President and CEO in June 1997.  He became Chairman of the Board and CEO in 1997, and Chairman on January 1, 2010.  During his tenure as CEO, Intuitive Surgical has grown from a start-up with no revenues to over one billion dollars in revenue and approximately 1300 employees.  Prior to joining Intuitive Surgical, Mr. Smith was Senior Executive Vice President of Hillenbrand Industries, which he joined in 1978.  During his tenure, he was a member of the executive committee, the office of the president and the board of directors. Mr. Smith has also held positions at The Boston Consulting Group and IBM. He received his B.S.E.E. from Utah State University and an M.B.A. from Harvard Business School.

Lawrence H. Summers is President Emeritus of Harvard University. During the past two decades he has served in a series of senior policy positions, including Vice President of development economics and chief economist of the World Bank, Undersecretary of the Treasury for International Affairs, Director of the National Economic Council for the Obama Administration from 2009 to 2011, and Secretary of the Treasury of the United States, from 1999 to 2001. He is currently the Charles W. Eliot University Professor at Harvard University.

Andrew J. Sussman, M.D., M.B.A. has been President of MinuteClinic, the largest retail clinic provider in the United States, since 2009, growing them over 40%, and expanding its scope of services and health system affiliations. He is also the SVP and Associate Chief Medical Officer of CVS/Caremark. 

He was previously Executive Vice President, Chief Operating Officer of UMass Memorial Medical Center, the largest healthcare provider in central New England, and was responsible for all clinical services and daily operations at the 800 bed academic medical center, the major teaching affiliate of UMass Medical School. Dr. Sussman is also an Associate Professor of Medicine at the University of Massachusetts Medical School.

Dr. Sussman is a graduate of Harvard Collegeand Harvard Medical School, as well as Boston University School of Management.  Before joining UMass Memorial in May 2004, Dr. Sussman served as Chief Medical Officer of the Brigham and Women’s Physicians Organization, a multi-specialty academic physician practice composed of 800 Harvard Medical School faculty members practicing at Brigham and Women’s Hospital.  At Brigham and Women’s Hospital, he also practiced primary care internal medicine and taught as an Assistant Professor of Medicine at Harvard Medical School.  He has published work on health systems, quality improvement, medical management, health care finance, and integrated clinical network operations.  He is listed among America’s Best Doctors.

Steve Wardell is a business development and corporate finance professional with transactional and company-building experience in e-health, health services, pharmaceuticals, biotechnology, and medical devices. Steve is Senior Director of Marketing and Business Development at Boston-based MedNetworks, Inc. MedNetworks is the world leader in developing an innovative analytic technology that integrates data to enable client companies to reach their customers more effectively by means of highly specific targeting information. Its network-analysis technology also discovers trends and prepares its customers to take advantage of future developments.

Prior to working in the Boston-area healthcare industry, Steve participated on Wall Street in over $20 billion worth of M&A and financing transactions at Citigroup in the healthcare, technology, and industrial sectors.

Chosen as one of Boston's "Top 40 Under 40" leaders by the Boston Business Journal, Steve was also named one of the "Top Outstanding Young Leaders" by the Greater Boston Jaycees.

He holds an MBA from Harvard Business School, an MPhil in Economics from Cambridge University, England, and a BA from Harvard College.

Dr. Westphal founded Longwood Founders Fund, a venture capital fund based in Boston, and serves as General Partner.

In addition to these roles, Dr. Westphal is the Co-Chair of the Scientific Advisory Board of Sirtris, which he co-founded in 2004 and led as Chief Executive Officer until 2010. Under his leadership, Sirtris established itself as a recognized pioneer in the research and development of drugs targeting the aging process enzymes. In 2007, Dr. Westphal successfully guided the company through its initial public offering, resulting in recognition by the Boston Globe as one of the Globe 100 top companies of 2007. In June 2008, GSK acquired Sirtris for $720 million.

Dr. Westphal was previously co-founder and CEO of Alnylam Pharmaceuticals, Momenta Pharmaceuticals and Acceleron Pharma. He also co-founded Alnara, which was sold to Eli Lilly for $380M in 2010. Prior to establishing Sirtris, Dr. Westphal was a general partner at a venture fund and a consultant with McKinsey & Company. He earned his M.D. from Harvard Medical School and Ph.D. in genetics from Harvard University; and he graduated with a B.A. summa cum laude and Phi Beta Kappa from Columbia University.

Dr. Westphal currently serves on the Board of Fellows of Harvard Medical School and the Board of Overseers of the Boston Symphony Orchestra. He has been the lead or senior author on several patent applications and scientific papers in journals, including Cell, Nature and Nature Genetics.

Dr. Westphal has received national recognition and a number of industry awards, including being named one of Fortune’s eight “Fortune Visionaries” in 2010; a Stevie Award for Executive of the Year from The 2009 American Business Awards; the 2009 E-3 Public Company Science & Technology Company Executive Award; 2008 Outstanding Individual of the Year Award at the annual Laguna Biotech CEO Meeting; 2008 Corporate Leader Award of Distinction from the American Federation for Aging Research (AFAR); recognition in the Pharmaceutical Executive “45 Under 45” and PharmaVOICE 100 issues, both in 2008; Mass High Tech All Star Award in 2007; and Ernst & Young’s New England Entrepreneur of the Year award in the Biopharmaceutical category in 2006.

In addition to being interviewed for numerous high-profile articles and broadcast segments, Dr. Westphal has been featured on 60 Minutes with Morley Safer, CNN’s Vital Signs with Dr. Sanjay Gupta, an ABC News Special hosted by Barbara Walters, and as the subject of a Fortune cover article. Dr. Westphal is also featured in two books – “Mastering the VC Game” by Jeff Bussgang and “The Youth Pill” by David Stipp.

Stephen Wiggins is a Managing Director of Essex Woodlands Health Ventures, America’s largest health care venture capital and growth equity firm with active investment practices in biotechnology, specialty pharmaceuticals, medical technology and health care services. Essex Woodlands manages eight health care funds and Stephen heads the New York Office.

Prior to Essex, Stephen was the founder and served 14 years as Chairman of the Board and Chief Executive Officer of Oxford Health Plans. Under his leadership, Oxford grew to over $5 billion of annual revenue and ranked among the 300 largest U.S. corporations. He was also the Founder, Chairman and Chief Executive Officer of HealthMarket, Inc, an insurance company that created innovative Consumer Driven Health Plans.

He co-founded Health Partners, Inc. in 1993, a physician practice management company. He was also a principal co-Founder of Intelliclaim, Inc., which provided claim auditing and productivity software and services to over twenty health insurers before it was sold to McKesson; and BenefitPort, LLC, a consolidation of health insurance general agencies.

Stephen Wiggins has also been an active private equity investor, and serves on the Board of Directors for Touchstone Health, Ika Systems, Centerstone Partners and Arrowhawk Capital. In 1978, he founded and remains a director of Accessible Space, Inc, a nonprofit organization that develops and operates 75 residential facilities for individuals with mobility impairments and brain injuries. He served 8 years on the Executive Committee of the Health Care Leadership Council and was appointed to the Presidential Commission on Health Care under President Bill Clinton.

Stephen Wiggins holds a Bachelor of Arts from Macalester College where he currently serves as a Trustee, and a Masters in Business Administration from Harvard Business School.